

10/552153

JC03 Rec'd PCT/PTO 11 OCT 2005

ADLER & ASSOCIATES

P.O. BOX 710509
HOUSTON, TEXAS 77271-0509

WRITER'S DIRECT DIAL
(713)-270-5391
WRITER'S DIRECT FACS.
(713)- 270-5361
E. MAIL: BADLER1@houston.rr.com

INTELLECTUAL PROPERTY LAW
(PATENT, BIOTECHNOLOGY, COMPUTER,
TRADEMARK & TRADE SECRET LAW)

October 11, 2005

Docket No.: D6486

MS PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request entry into the US national stage under 35 U.S.C. 371 and 37 C.F.R. 1.495 of international application PCT/US2004/010832, filed April 8, 2004, now abandoned, the specification of which was communicated to the United States Patent Office by the International Bureau under PCT Article 20 on August 11, 2005, and which international application claims benefit of priority under 35 USC 119(e) of provisional U.S. Serial no. 60/461,474 filed April 9, 2003, now abandoned, in the:

Name of: **Mohamadzadeh et al.**
For: ***Dendritic Cell binding Proteins and Uses Thereof***

CLAIMS AS FILED

<u>Fee for:</u>	<u>Small entity</u>	<u>Amount</u>
Basic National Stage Fee	\$150	\$150
Search Fee (37 CFR 1.492(b)(1))	\$ 0	\$ 0
Examination Fee (37 CFR 1.492(c)(1))	\$ 0	\$ 0
Each independent claim		
in excess of 3 (1)	\$100	\$100
Each claim excess of 20 (14)	\$ 25	\$350
Additional pages over 100;		
for every 50 pages	\$125	\$ 0
Multiple dependent claim		
TOTAL FILING FEE		\$600

JC09 Rec'd PCT/PTO 11 OCT 2005

☒ Please charge the credit card identified on Form PTO-2038 in the total amount of the filing fee and the assignment recordation fee, if any.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Acct. No. 07-1185.

☒ Any additional fees under 37 CFR 1.16.

☒ Any application processing fees under 37 CFR 1.17.

☒ Small Entity Status

Applicants hereby claim small entity status under 37 CFR 1.27(a).

☒ Relate Back--35 U.S.C. 119(e)

This US national stage application claims benefit of priority of international application PCT/US2004/010832, filed April 8, 2004, now abandoned, which claims benefit of priority under 35 USC 119(e) of provisional application U.S. Serial no. 60/461,474 filed April 9, 2003, now abandoned.

☐ Assignment

The application is assigned by the inventors to the _____.

☒ Sequence Listing

A computer readable form of the sequence listing and a compliance letter indicating that the sequence listing on the paper copy originally filed with international application PCT/US2004/010832 and the disk are one and the same.

☒ Drawings

Figures 1A-1F, 2A-2E, 3A-3C, 4A-4C, 5A-5F, 6A-6F, 7A-7D, 8A-8C, and 9A-9B on 23 sheets were filed with international application PCT/US2004/010832.

☒ Power of Attorney


☒ is attached.

☒ Address all future communications to:

Benjamin Aaron Adler
ADLER & ASSOCIATES
8011 Candle Lane
Houston TX 77071
(713) 271-5391
BADLER1@houston.rr.com

☒ Two photocopies of this sheet are enclosed.

Date: Oct 11, 2005


Benjamin Aaron Adler, Ph.D., J.D.
Counsel for Applicant
Registration No. 35,423

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Mohamadzadeh et al.

§ ART UNIT:

FILED: October 11, 2005

§

§

§

EXAMINER:

SERIAL NO.:

§

§

§

FOR: Dendritic Cell Binding Proteins
and Uses Thereof

§

DOCKET:

D6486

MS PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

Dear Sir:

I hereby certify that the following documents, which are attached, are being deposited, under 37 CFR 1.10, with the United States Postal Service "Express Mail Post Office to Addressee" service as Express Mail No. EV704584669US in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

- 1) U.S. National Stage Transmittal Letter;
- 2) Preliminary Amendment;
- 3) CRF of sequence listing and compliance statement;
- 4) Three (3) Combined Declarations and Powers of Attorney; and
- 5) Form PTO-2038.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: Oct. 11, 2005
ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
Tel.: (713)-270-5391
Fax: (713) 270-5361
badler1@houston.rr.com

Colleen M. Werner
Colleen M. Werner

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Mohamadzadeh et al.

§ ART UNIT:

FILED: October 11, 2005

§

§

§

EXAMINER:

SERIAL NO.:

§

§

§

DOCKET:

FOR: Dendritic Cell Binding Proteins
and Uses Thereof

§

D6486

MS PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


COMPLIANCE OF REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

Dear Sir:

Applicant provides a computer readable form of the Sequence Listing on the enclosed 3.5 inch disk for the above-referenced US national stage application. A paper copy thereof was filed with international application PCT/US2004/010832 on April 8, 2004. The disk is a 1.44 Mb PC-formatted disk. The file is stored as D6486SEQ in text format. I hereby state that the content of the Sequence Listing filed as part of the international application and the enclosed computer readable copy of the Sequence Listing are the same.

Respectfully submitted,

Date: Oct 11, 2005
ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
Tel.: (713)-270-5391
Fax: (713) 270-5361
badler1@houston.rr.com


Benjamin Aaron Adler, Ph.D., J.D.
Counsel for Applicant
Registration No. 35,423